The Innovation Fund invests in the development of CYM-001, an innovative Bispecific Antibody to treat Metastatic castration- resistant Prostate Cancer (BAMPC)
Ryan Polito2024-08-01T13:56:31+00:00The Innovation Fund invests in the development of CYM-001, an innovative Bispecific Antibody to treat Metastatic castration- resistant Prostate Cancer (BAMPC) September 13, 2023 The Innovation Fund has invested approximately DKK 12.3 million in a research project aimed at developing a biological drug candidate that represents a completely new concept in cancer treatment. The molecule, [...]